MLAB files a Form 144 notice to sell 2,516 shares of Common Stock. The filing lists 2,516 shares associated with a Restricted Stock Vesting event dated 06/18/2026. It also reports 1,151 shares sold during the prior three months on 06/16/2026 with an associated figure of $116,558.32.
Mesa Laboratories senior vice president of operations Brian David Archbold reported an open-market sale of company stock. On June 16, 2026, he sold 1,151 shares of Mesa Laboratories common stock at an average price of $101.267 per share. After this transaction, he continues to hold 3,710 shares directly.
Mesa Laboratories Chief Accounting Officer Lyndsey Elizabeth Crennen reported an open-market sale of common stock. On June 16, 2026, she sold 118 shares of Mesa Laboratories common stock at an average price of $101.267 per share. According to the footnote, the shares were sold to cover taxes due on restricted stock units (RSUs) that vested on June 15, 2026, indicating a tax-related transaction rather than a discretionary portfolio move. Following this sale, Crennen directly holds 1,473 shares of Mesa Laboratories common stock.
Mesa Laboratories CFO John Sakys reported an insider transaction involving company common stock. On June 16, 2026, he sold 1,223 shares in an open-market sale at $101.267 per share to cover taxes arising from the vesting of restricted stock units on June 15, 2026. After this sale, he directly holds 16,538 Mesa Laboratories shares. In addition, 50 shares are held indirectly for his children, where he acts as custodian.
Mesa Laboratories Inc. executive Lyndsey Elizabeth Crennen, Chief Accounting Officer, has filed an initial statement of ownership showing her equity stake in the company. The filing lists existing holdings and does not report new open‑market trades.
She directly holds 1,863 shares of Common Stock. In addition, she holds several non‑qualified stock option awards, including options over 369 shares at an exercise price of $268.85 per share expiring on September 1, 2027, 488 shares at $185.57 expiring on June 15, 2028, and 646 shares at $131.67 expiring on June 21, 2029.
Crennen also holds multiple restricted stock unit (RSU) awards, each representing a contingent right to receive one share of common stock. These RSUs cover blocks such as 1,800 shares, 1,443 shares, 735 shares, 542 shares, 465 shares, and 125 shares, with vesting schedules that extend in tranches through 2029.
Mesa Laboratories executive Brian David Archbold reported compensation-related equity changes. On June 15, 2026, he exercised derivative awards to acquire 2,454 shares of Mesa Laboratories common stock at $104.08 per share, increasing his direct common stock holdings to 4,861 shares.
He also received a new grant of 4,328 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in stages starting on June 15, 2026. In addition, 1,780 Non Qualified Stock Options with a $226.72 exercise price reached expiration.
Following these transactions, Archbold holds 4,328 RSUs and 11,852 Non Qualified Stock Options alongside his common shares, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Mesa Laboratories CFO John Sakys reported compensation-related equity changes. He exercised derivative awards to acquire 2,717 shares of common stock, bringing his direct holdings to 17,761 shares. He also received a grant of 8,416 restricted stock units, each representing one future share of common stock.
In addition, 3,951 non-qualified stock options with a $226.72 exercise price reached expiration. Sakys also reports 50 shares of common stock held indirectly as custodian for his children.